Leaders Free ACS: Good Results for the Polymer-Free Stent at 2 Years in ACS

 Courtesy of the SBHCI.

Leaders Free ACS: Good Results for the Polymer-Free Stent at 2 Years in ACSGuidelines recommend dual antiplatelet therapy for a year in patients admitted with coronary acute syndrome. However, patients at high risk for bleeding who receive coronary angioplasty have been historically excluded from studies. The new polymer-free stent BioFreedom allows for the reduction of dual antiplatelet therapy time, due to rapid drug elution into the vessel wall.

 

The study randomized patients at high risk for bleeding to receive the drug-coated stent BioFreedom or a corresponding conventional stent (bare metal stent). The primary safety endpoint was a composite of cardiac death, infarction, and definite or probable stent thrombosis. The primary efficacy endpoint was target vessel revascularization clinically justified at a year.

 

The study enrolled 662 patients; 33% of patients had diabetes and 84% were admitted with non-ST-segment elevation coronary syndrome. The BioFreedom stent was superior as regards both the primary safety endpoint (13% vs. 21.5%; p = 0.005) and the primary efficacy endpoint (5% vs. 10.4%; p = 0.009).

 

An analysis of separate safety endpoint components showed that the advantage of BioFreedom was driven by the rate of infarction (9% vs. 15.7%; p = 0.01), since all other components (cardiac death, definite or probable thrombosis, and bleeding) turned out to be similar.

 

Conclusion

Absolute differences observed at the 1-year follow-up were still present at 2 years. From a clinical point of view, conventional stents are not indicated in patients at high risk for bleeding with acute coronary syndrome anymore.

 

Courtesy of the SBHCI.

 

Dra. Marie Claude Morice
Dra. Marie Claude Morice

Original title: Leaders Free ACS: 2-Year Follow Up.

Presenter: Marie Claude Morice.

 

 

Morice-Marie-Claude


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...